Cargando…

Myotonic Dystrophies: State of the Art of New Therapeutic Developments for the CNS

Myotonic dystrophies are multisystemic diseases characterized not only by muscle and heart dysfunction but also by CNS alteration. They are now recognized as brain diseases affecting newborns and children for myotonic dystrophy type 1 and adults for both myotonic dystrophy type 1 and type 2. In the...

Descripción completa

Detalles Bibliográficos
Autores principales:	Gourdon, Genevieve, Meola, Giovanni
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2017
Materias:	Neuroscience
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5397409/ https://www.ncbi.nlm.nih.gov/pubmed/28473756 http://dx.doi.org/10.3389/fncel.2017.00101

Ejemplares similares

Therapeutic Targeting of the GSK3β-CUGBP1 Pathway in Myotonic Dystrophy
por: Lutz, Maggie, et al.
Publicado: (2023)

Current Progress in CNS Imaging of Myotonic Dystrophy
por: Minnerop, Martina, et al.
Publicado: (2018)

Of Mice and Men: Advances in the Understanding of Neuromuscular Aspects of Myotonic Dystrophy
por: Braz, Sandra O., et al.
Publicado: (2018)

Excessive rest time during active phase is reliably detected in a mouse model of myotonic dystrophy type 1 using home cage monitoring
por: Golini, Elisabetta, et al.
Publicado: (2023)

Myotonic dystrophy type 2: the 2020 update
por: Meola, Giovanni
Publicado: (2020)

RNA Transcription and Maturation in Skeletal Muscle Cells are Similarly Impaired in Myotonic Dystrophy and Sarcopenia: The Ultrastructural Evidence
por: Malatesta, Manuela, et al.
Publicado: (2014)

Clinical aspects, molecular pathomechanisms and management of myotonic dystrophies
por: MEOLA, GIOVANNI
Publicado: (2013)

Core Clinical Phenotypes in Myotonic Dystrophies
por: Wenninger, Stephan, et al.
Publicado: (2018)

Cells of Matter—In Vitro Models for Myotonic Dystrophy
por: Matloka, Magdalena, et al.
Publicado: (2018)

Brain Pathogenesis and Potential Therapeutic Strategies in Myotonic Dystrophy Type 1
por: Liu, Jie, et al.
Publicado: (2021)

Editorial: Beyond Borders: Myotonic Dystrophies–A European Perception
por: Schoser, Benedikt, et al.
Publicado: (2018)

Functional and histopathological identification of the respiratory failure in a DMSXL transgenic mouse model of myotonic dystrophy
por: Panaite, Petrica-Adrian, et al.
Publicado: (2013)

RBFOX1 Cooperates with MBNL1 to Control Splicing in Muscle, Including Events Altered in Myotonic Dystrophy Type 1
por: Klinck, Roscoe, et al.
Publicado: (2014)

TNNT2 Missplicing in Skeletal Muscle as a Cardiac Biomarker in Myotonic Dystrophy Type 1 but Not in Myotonic Dystrophy Type 2
por: Bosè, Francesca, et al.
Publicado: (2019)

Deregulated MicroRNAs in Myotonic Dystrophy Type 2
por: Greco, Simona, et al.
Publicado: (2012)

Myotonic dystrophy
por: Patterson, VH
Publicado: (1990)

Overexpression of CUGBP1 in Skeletal Muscle from Adult Classic Myotonic Dystrophy Type 1 but Not from Myotonic Dystrophy Type 2
por: Cardani, Rosanna, et al.
Publicado: (2013)

Muscle wasting in myotonic dystrophies: a model of premature aging
por: Mateos-Aierdi, Alba Judith, et al.
Publicado: (2015)

Abnormalities in Skeletal Muscle Myogenesis, Growth, and Regeneration in Myotonic Dystrophy
por: André, Laurène M., et al.
Publicado: (2018)

Myotonic Dystrophy Type 2: An Update on Clinical Aspects, Genetic and Pathomolecular Mechanism
por: Meola, Giovanni, et al.
Publicado: (2015)

Electrophysiological basis of cardiac arrhythmia in a mouse model of myotonic dystrophy type 1
por: Ginjupalli, Vamsi Krishna Murthy, et al.
Publicado: (2023)

Synaptic protein dysregulation in myotonic dystrophy type 1: Disease neuropathogenesis beyond missplicing
por: Hernández-Hernández, Oscar, et al.
Publicado: (2013)

Myotonic Dystrophy: From Molecular Pathogenesis to Therapeutics
por: Timchenko, Lubov
Publicado: (2022)

Myotonic dystrophy type 1 in the COVID-19 era
por: Ilic Zivojinovic, Jelena, et al.
Publicado: (2023)

Autoimmune Diseases in Patients With Myotonic Dystrophy Type 2
por: Peric, Stojan, et al.
Publicado: (2022)

Brain pathology in myotonic dystrophy: when tauopathy meets spliceopathy and RNAopathy
por: Caillet-Boudin, Marie-Laure, et al.
Publicado: (2014)

Small Molecules Which Improve Pathogenesis of Myotonic Dystrophy Type 1
por: López-Morató, Marta, et al.
Publicado: (2018)

Increased functional connectivity of white-matter in myotonic dystrophy type 1
por: Li, Jing, et al.
Publicado: (2022)

Molecular and Clinical Implications of Variant Repeats in Myotonic Dystrophy Type 1
por: Peric, Stojan, et al.
Publicado: (2021)

Cancer and Myotonic Dystrophy
por: D’Ambrosio, Eleonora S., et al.
Publicado: (2023)

Development of Therapeutic Approaches for Myotonic Dystrophies Type 1 and Type 2
por: Timchenko, Lubov
Publicado: (2022)

Antisense oligonucleotides as a potential treatment for brain deficits observed in myotonic dystrophy type 1
por: Ait Benichou, Siham, et al.
Publicado: (2022)

Clinical score for early diagnosis of myotonic dystrophy type 2
por: Ivanovic, Vukan, et al.
Publicado: (2022)

CTG-Repeat Detection in Primary Human Myoblasts of Myotonic Dystrophy Type 1
por: Hintze, Stefan, et al.
Publicado: (2021)

MicroRNA-Based Therapeutic Perspectives in Myotonic Dystrophy
por: López Castel, Arturo, et al.
Publicado: (2019)

Dysregulation of Circular RNAs in Myotonic Dystrophy Type 1
por: Voellenkle, Christine, et al.
Publicado: (2019)

Myotonic dystrophy: new clues from flies
Publicado: (2013)

Targeting DMPK with Antisense Oligonucleotide Improves Muscle Strength in Myotonic Dystrophy Type 1 Mice
por: Jauvin, Dominic, et al.
Publicado: (2017)

Steakhouse Syndrome in Myotonic Dystrophy
por: Ogasawara, Nobuhiko, et al.
Publicado: (2017)

Neuropsychological and Psychological Functioning Aspects in Myotonic Dystrophy Type 1 Patients in Italy
por: Callus, Edward, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_213ib5c7pmeaum0smu0jou6eda